Safety and Efficacy of Long-term Somatropin Treatment in Adults (NordiWIN)

Novo Nordisk

Status: Completed

Conditions: Adult Growth Hormone Deficiency; Growth Hormone Disorder

Treatments: Drug: somatropin

Study type: Observational

Funder types: Industry

Identifiers

NCT01543880

GH-1931

Details and patient eligibility

About

This study is conducted in Europe. The aim of the study is to evaluate safety and efficacy in adults treated with somatropin (Norditropin®).

Enrollment: 752 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• In need of somatropin or current user

Trial design

752 participants in 1 patient group

Users of somatropin

Treatment:

Drug: somatropin